AB-3PRGD2

Overview

AB-3PRGD2 is a radiotherapeutic agent targeting integrin α v β 3 . AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8 + T cells.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > PD-1/PD-L1 | Products > Signaling Pathways > Integrin

Product Information

• Catalog No.: HY-171331
• CAS No.: 2416165-76-7
• Molecular Formula: C137H215IN30O45S
• Molecular Weight: 3161.32
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source